Development and stability assessment of liquid paediatric formulations containing sildenafil citrate
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10314/2485 |
Resumo: | The purpose of this study is to develop and improve oral liquids formulations of sildenafil citrate for paediatric use. Four different formulations were developed, which are as follows: two aqueous solutions of sildenafil citrate (2.5 mg/mL), with or without preservatives, and two other solutions of sildenafil in simple syrup (1.25 mg/mL), with or without preservatives. All of the formulations were physically, chemically and microbiologically stable for three months. The results of the stability studies allowed for the optimisation of formulations without preservatives due to their simplicity and their similar stable conditions when compared to the formulations containing antimicrobials. The shelf life of both formulations was three months; however, upon opening, aqueous solutions should be used within 10 days and kept refrigerated, and syrup solutions should be used within 14 days in a hospital setting. |
id |
RCAP_d0598741bcd824eae2c51a763afc347e |
---|---|
oai_identifier_str |
oai:bdigital.ipg.pt:10314/2485 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrateChemical stabilityMicrobiological stabilitySildenafil citratePaediatric formulationsThe purpose of this study is to develop and improve oral liquids formulations of sildenafil citrate for paediatric use. Four different formulations were developed, which are as follows: two aqueous solutions of sildenafil citrate (2.5 mg/mL), with or without preservatives, and two other solutions of sildenafil in simple syrup (1.25 mg/mL), with or without preservatives. All of the formulations were physically, chemically and microbiologically stable for three months. The results of the stability studies allowed for the optimisation of formulations without preservatives due to their simplicity and their similar stable conditions when compared to the formulations containing antimicrobials. The shelf life of both formulations was three months; however, upon opening, aqueous solutions should be used within 10 days and kept refrigerated, and syrup solutions should be used within 14 days in a hospital setting.Brazilian Journal of Pharmaceutical Sciences2016-07-272013-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10314/2485http://hdl.handle.net/10314/2485eng1984-8250Roque, FátimaRama, Ana CristinaSousa, João JoséPina, Maria Eugéniainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-01-14T02:55:26Zoai:bdigital.ipg.pt:10314/2485Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:42:04.230747Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
title |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
spellingShingle |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate Roque, Fátima Chemical stability Microbiological stability Sildenafil citrate Paediatric formulations |
title_short |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
title_full |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
title_fullStr |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
title_full_unstemmed |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
title_sort |
Development and stability assessment of liquid paediatric formulations containing sildenafil citrate |
author |
Roque, Fátima |
author_facet |
Roque, Fátima Rama, Ana Cristina Sousa, João José Pina, Maria Eugénia |
author_role |
author |
author2 |
Rama, Ana Cristina Sousa, João José Pina, Maria Eugénia |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Roque, Fátima Rama, Ana Cristina Sousa, João José Pina, Maria Eugénia |
dc.subject.por.fl_str_mv |
Chemical stability Microbiological stability Sildenafil citrate Paediatric formulations |
topic |
Chemical stability Microbiological stability Sildenafil citrate Paediatric formulations |
description |
The purpose of this study is to develop and improve oral liquids formulations of sildenafil citrate for paediatric use. Four different formulations were developed, which are as follows: two aqueous solutions of sildenafil citrate (2.5 mg/mL), with or without preservatives, and two other solutions of sildenafil in simple syrup (1.25 mg/mL), with or without preservatives. All of the formulations were physically, chemically and microbiologically stable for three months. The results of the stability studies allowed for the optimisation of formulations without preservatives due to their simplicity and their similar stable conditions when compared to the formulations containing antimicrobials. The shelf life of both formulations was three months; however, upon opening, aqueous solutions should be used within 10 days and kept refrigerated, and syrup solutions should be used within 14 days in a hospital setting. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-06-01T00:00:00Z 2016-07-27 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10314/2485 http://hdl.handle.net/10314/2485 |
url |
http://hdl.handle.net/10314/2485 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1984-8250 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences |
publisher.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799136912376594432 |